MCA Scientific Events 4th Congress on Congenital Cytomegalovirus 2025

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Obstetricians, Gynecologists, Pediatricians, Neonatologists, Infectious Disease Specialists, Virologists, Audiologists, and Immunologists

+ Sample video: contact me for sample video

+ Information:

The 4th Congress on Congenital Cytomegalovirus, titled “From Pregnancy to Infancy: Let’s face it,” will be held in Naples, Italy, on 20 – 21 November 2025. Online participation is available. The congress is led by Presidents Yves Ville (France), Efraim Bilavsky (Israel), and Francesco Raimondi (Italy).

Learning Objectives

• To explore and evaluate screening strategies for CMV in pregnancy across different countries.

• To analyze the complexities and implementation of serological assays for maternal CMV non-primary infections.

• To understand the role of prenatal diagnosis tools, including NIPT, invasive prenatal diagnosis, and digital PCR.

• To review the prognosis of fetal infections, integrating the use of ultrasound, MRI, and the pharmacology of antiviral drugs in pregnancy.

• To discuss the current and future impacts of congenital CMV on children, including inner ear development, neurological disorders, and autism spectrum links.

• To assess the characteristics and progression of hearing loss in children with congenital CMV and debate the efficacy of antiviral treatments.

• To examine the progress and future prospects of realizing a vaccine for the prevention of congenital CMV.

Target Audience

• This congress is designed for healthcare professionals, researchers, and specialists dedicated to the study, diagnosis, and treatment of congenital Cytomegalovirus (cCMV) from the prenatal stage through infancy.
• Best for Obstetricians, Gynecologists, Pediatricians, Neonatologists, Infectious Disease Specialists, Virologists, Audiologists, and Immunologists.

Topics

Thursday, 20 November 2025

• 09:00 – 09:10 | WELCOME FROM CONGRESS PRESIDENTS: Yves Ville (France), Francesco Raimondi (Italy), Efraim Bilavsky (Israel)

• 09:10 – 10:40 | SESSION 1 – SCREENING IN PREGNANCY (Chairs: Yves Ville, France; Tiziana Lazzaroto, Italy)

  • 09:10 – 09:40 | Screening in pregnancy, in Italy and in France

    • Oral Communication: Outcome of primary CMV infection in pregnancy in Italy: data from a large multicentric cohort before and after the introduction of valacyclovir in the clinical practice at country level (Lorenzo Zammarchi, Italy)

    • Oral Communication: Congenital Cytomegalovirus Infection in Children Born to Mothers with Primary CMV Infection Treated with Valaciclovir: Analysis of the Multi-center MEGAL-ITALI Study (Elisabetta Venturini, Italy)

    • Oral Communication: Implementation of a national system for reporting and monitoring primary maternal CMV infections in France, in response to the HAS recommendations (Sophie Alain, France)

  • 09:40 – 10:00 | Serology made simple, or nearly (Marianne Leruez Ville, France)

  • 10:00 – 10:20 | How can we help pre-immune women? (Daniele Lilleri, Italy)

  • 10:20 – 10:40 | Discussion

• 10:40 – 11:20 | SESSION 2 – Oral communications (Chairs: Anna Gonce, Spain; Christelle Vauloup-Fellous, France)

  • Oral Communication: Occurrence of situations in which early CMV screening serology (<14 weeks of gestation) poses interpretative challenges (Christelle Vauloup-Fellous, France)

  • Oral Communication: CMV-Scan: a highly sensitive serological assay to detect maternal CMV non-primary infection (Ariane Larouche, Canada)

  • Oral Communication: Reduction of voluntary termination of pregnancy in pregnant women with primary Cytomegalovirus infections treated with valaciclovir (Alice Bonetti, Italy)

  • Oral Communication: Evolving Trends in Maternal Screening and First-Trimester Treatment: Data from the French National Herpesvirus Reference Center (Elodie Ribot, France)

  • Oral Communication: Beyond the Tip of the Iceberg: The Clinical Impact of Maternal Non-Primary CMV Infection ICCG- Israel Congenital CMV Group (Goni Peleg, Israel)

• 11:30 – 12:00 | COFFEE BREAK

• 12:00 – 14:10 | SESSION 3 – PRENATAL DIAGNOSIS (Chairs: Valentine Faure-Bardon, France; Marie-Luce Delforge, Belgium)

  • NIPT for CMV in pregnancy (Brigitte Faas, The Netherlands)

  • Invasive prenatal diagnosis (Nicolas Bourgon, France)

  • Is there more for serology to say? (Alfred Bissinger, Germany (online))

  • Secondary prevention, an international registry (Christros Chatzakis, United Kingdom)

  • 13:20 – 13:40 | Discussion

• 13:40 – 14:30 | LUNCH / POSTER VIEWING

• 14:30 – 15:20 | SESSION 4 – Oral Communications (Chairs: Jacques Fourgeaud, France; Caroline De Coninck, Belgium)

  • Beyond Real-Time PCR: diagnostic accuracy of Digital PCR in the Pre-natal Diagnosis of Congenital CMV Infection (Liliana Gabrielli, Italy)

  • High-Dose Valacyclovir in Primary Cytomegalovirus Infection During Pregnancy: Effects on Immune Modulation and Maternal Serologic Response (Silvio Tartaglia, Italy)

  • Successful prevention of fetal CMV infection by valacyclovir and the interval between maternal infection and treatment initiation, a retrospective study (Jacob Amir, Israel)

  • Evaluation of MyCMV: A Tool to Enhance the Diagnosis of Cytomegalovirus Infection During Pregnancy (Jacques Fourgeaud, France)

  • Discussion

• 15:20 – 15:50 | COFFEE BREAK

• 15:50 – 17:20 | SESSION 5 – PROGNOSIS OF FETAL INFECTION (Chairs: Olivier Picone, France; Francesco Raimondi, Italy)

  • How to combine ultrasound and MRI? (Yves Ville, France)

  • Biology of an infected fetus for best and for worse (Anna Gonce, Spain)

  • Pharmacology of antiviral drugs in pregnancy (Valentine Faure-Bardon, France)

  • 16:50 – 17:20 | Discussion

• 17:20 – 18:10 | SESSION 6 – Oral communications (Chairs: Alfred Bissinger, Germany (online); Hermione Lyall, United Kingdom)

  • Inhibitory effect of antivirals on CMV infection in human stem cell-derived neural systems (Renata Vieira De Sa, The Netherlands)

  • Rate of post-amniocentesis transmission in pregnant women with primary cytomegalovirus infection treated with valaciclovir (Piera d’Angelo, Italy)

  • Congenital cytomegalovirus causes increased expression of neutrophil granule genes and suppression of innate immune response genes (Helen Payne, United Kingdom)

  • 18:00 – 18:10 | (Reserved block, unspecified details)

Friday, 21 November 2025

• 09:00 – 11:00 | SESSION 7 – The present and future of children with congenital CMV (Chairs: Ann Vossen, Belgium; Jacob Amir, Israel)

  • Impact of CMV on the Inner Ear – Looking through the Developmental Lens (Sharon Cushing, Canada)

  • Redefining the “Asymptomatic” Child in the Emerging Era of Universal cCMV Screening (Mark Schleiss, United States)

  • The link between cCMV and the autistic spectrum? (Marianne Leruez Ville & David Grévent, France)

  • How Close Are We? Prospects and Predicaments in Realizing the Goal of Licensing a Vaccine for Prevention of Congenital CMV (Mark Schleiss, United States)

  • Oral Communication: Beyond Hearing and Vision: Pilot Data on Olfactory Function in Congenital Cytomegalovirus (Serena Salomè, Italy)

  • Oral Communication: cCMV infection and risk of autism spectrum and other neurodevelopmental disorders in a large patient population in Northern California (Tara Greenhow, United States)

  • Oral Communication: Educational attainment, absenteeism, and special educational needs outcomes in school children up to age 10/11 with congenital cytomegalovirus (cCMV): A population-based cohort study using linked education and hospital data from England (Ayana Cant, United Kingdom)

  • 11:00 – 11:30 | Discussion

• 11:30 – 12:20 | COFFEE BREAK & POSTER WALK

• 12:20 – 13:30 | SESSION 8 – Hearing loss on children with congenial CMV (Chairs: Anna Rita Fetoni, Italy; Efraim Bilavsky, Israel)

  • Characteristics of Progression in Hearing Loss in Children with cCMV (Sharon Cushing, Canada)

  • An Enzymatic Assay for Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus (Willow Chernoske, United States)

  • CMV-specific IFN-γ responses post QuantiFERON CMV test at birth correlate with symptoms at birth and long-term outcome in infants with congenital cytomegalovirus infection (Vana Papaevangelo, Greece)

  • 13:00 – 13:30 | Discussion

• 13:30 – 14:30 | LUNCH AND POSTER VIEWING

• 14:30 – 15:00 | Debate on Antiviral treatment in children with late onset hearing loss

  • PRO – Efraim Bilavsky, Israel

  • CONS – Ann Vossen, Belgium

• 15:00 – 15:15 | Discussion

• 15:15 – 15:30 | CLOSING REMARKS: Yves Ville (France), Francesco Raimondi (Italy), Efraim Bilavsky (Israel)